Lund Melanoma Study Group
41 – 50 of 225
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine
(
- Contribution to journal › Article
-
Mark
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
(
- Contribution to journal › Article
-
Mark
The Prognostic Impact of Intratumoral Aryl Hydrocarbon Receptor in Primary Breast Cancer Depends on the Type of Endocrine Therapy : A Population-Based Cohort Study
(
- Contribution to journal › Article
-
Mark
BRN2 is a non-canonical melanoma tumor-suppressor
(
- Contribution to journal › Article
-
Mark
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
(
- Contribution to journal › Article
-
Mark
Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence : A Nested Case-Control Study
(
- Contribution to journal › Article
-
Mark
Difference in Sun Exposure Habits Between Individuals with High and Low Risk of Skin Cancer
(
- Contribution to journal › Article
-
Mark
Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens
(
- Contribution to journal › Article
-
Mark
Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma
(
- Contribution to journal › Article
-
Mark
Trend shifts in age-specific incidence for in situ and invasive cutaneous melanoma in sweden
(
- Contribution to journal › Article